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Educational aims
●● To understand the role of Clinical Research Collaborations as the major way in which the European 
Respiratory Society can stimulate clinical research in different disease areas
●● To understand some of the key features of successful disease registries
●● To review key epidemiological, clinical and translational studies of bronchiectasis contributed by 
the European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) project in the 
past 5 years
●● To understand the key research priorities identified by EMBARC for the next 5 years
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In contrast to airway diseases like chronic obstructive pulmonary disease or asthma, and 
rare diseases such as cystic fibrosis, there has been little research and few clinical trials in 
bronchiectasis. Guidelines are primarily based on expert opinion and treatment is challenging 
because of the heterogeneous nature of the disease.
In an effort to address decades of underinvestment in bronchiectasis research, education 
and clinical care, the European Multicentre Bronchiectasis Audit and Research Collaboration 
(EMBARC) was established in 2012 as a collaborative pan-European network to bring together 
bronchiectasis researchers. The European Respiratory Society officially funded EMBARC in 2013 
as a Clinical Research Collaboration, providing support and infrastructure to allow the project 
to grow.
EMBARC has now established an international bronchiectasis registry that is active in more 
than 30 countries both within and outside Europe. Beyond the registry, the network participates 
in designing and facilitating clinical trials, has set international research priorities, promotes 
education and has participated in producing the first international bronchiectasis guidelines. 
This manuscript article the development, structure and achievements of EMBARC from 2012 
to 2017.
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Patients with bronchiectasis typically suffer 
from cough, sputum production, frequent chest 
infections and a number of other symptoms on 
a daily basis [1, 2]. In addition, patients have to 
struggle with the uncertainty provoked by frequent, 
unpredictable disease exacerbations [3, 4]. On top 
of the physical symptoms, patients have to deal with 
a diagnostic delay that is not infrequently more than 
https://www.linkedin.com/company/
embarc-the-european-bronchiectasis-
register
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a decade, and many patients are acutely aware that 
primary care physicians and nonspecialists know 
little about their condition, and that the evidence 
base for treatment is poor [5, 6].
Bronchiectasis has been described as an 
orphan disease but while the European Union 
(EU) defines an orphan or rare disease as one 
affecting fewer than one in 2000 people, the latest 
estimates suggest that bronchiectasis is relatively 
common [7–10]. Most recent estimates place the 
true prevalence at one in 206 for men and one 
in 176 for women in the UK, one in 276 persons 
in Catalonia (Spain), and one in 1492 persons in 
Germany [7–10]. Bronchiectasis is therefore not an 
orphan disease in the true sense of prevalence but 
has the characteristics of an orphan disease in terms 
of a weak evidence base, a lack of attention from 
scientists, clinicians, regulators and funders, and 
an absence of high-quality randomised controlled 
trials [11–13].
Although guidelines on the management 
of cough from CHEST in the USA in 2006 may 
be regarded as one of the first guidelines for 
bronchiectasis, the first guidelines to attempt to 
cover the totality of investigation and management 
of bronchiectasis worldwide were the Spanish 
(SEPAR) guidelines published in 2008 and 
subsequently the British Thoracic Society Guidelines 
in 2010 [12, 14, 15]. A reflection of poor state of 
evidence at that time is the fact that only three 
recommendations in the ≥200-page British 
Thoracic Society document were given a grade A 
recommendation, meaning the authors had a high 
degree of confidence in the recommendation [12]. 
These were to screen for antibody deficiency by 
measuring immunoglobulins, to offer physiotherapy 
exercises such as the active cycle of breathing 
technique and that recombinant DNAse should 
not be used for treatment [12, 16]. The majority of 
treatment recommendations were given a Grade D 
recommendation indicating expert opinion in the 
absence of robust evidence [12].
Europe has contributed a substantial majority of 
the published data on bronchiectasis over the past 
20 years. A systematic review by Aliberti et al. [17] 
(2000–2015) showed that even within Europe, the 
majority of published studies were from the UK, 
with further contribution from Spain, Italy and other 
Western European countries but with a paucity of 
published data from Eastern Europe (figure 1). 
Collaborative studies involving data from more 
than one European country could not be identified 
prior to 2014.
The backdrop to the development of the 
European Multicentre Bronchiectasis Audit and 
Research Collaboration (EMBARC) project was 
therefore a common and disabling chronic disease, 
a limited research and evidence base, a hostile 
funding environment, and an absence of pan-
European cooperation and coordination.
What is EMBARC?
EMBARC was established in 2012 as a collaborative 
group within European Respiratory Society (ERS) 
Assembly 10 (Respiratory Infections) with the 
objective of creating a European bronchiectasis 
registry, harmonising existing databases, and 
identifying opportunities to raise the profile of 
bronchiectasis at ERS and EU levels [18, 19].
In 2013, EMBARC applied to become an 
ERS Clinical Research Collaboration (CRC). ERS 
contributes to the coordination of activities in 
respiratory medicine across Europe by funding CRCs, 
which are designed as pan-European networks 
aiming to create a critical mass of research expertise 
to improve clinical research within a specific disease 
area [20]. EMBARC was one of the first ERS CRCs 
to be funded (in 2013, with funding running from 
2014 to 2017). The portfolio of CRCs is now highly 
diverse, covering disease areas from sleep apnoea, 
intensive care unit-related respiratory infections, 
childhood and adult interstitial lung diseases, severe 
asthma, and pulmonary function [20, 21].
CRCs stimulate research in a number of ways. 
In addition to funding, they provide access to 
the considerable resources of the ERS, providing 
access to ERS members, national delegates 
and national societies through the Forum of 
International Respiratory Societies (FIRS) (https://
www.firsnet.org/news-and-actions). They provide 
the ability to hold meetings and symposia at the 
ERS International Congress and, perhaps most 
importantly in the case of EMBARC, they provide 
an identity and mark of approval to the network, 
which enables the network to recruit both funders 
and participants through the trust that individual 
healthcare professionals, patients and funders have 
in the ERS [20, 21].
>40 studies
11–15 studies
16–20 studies
6–10 studies
<5 studies
Figure 1 Published original research studies in 2000–2015 on adult bronchiectasis worldwide 
(excluding cystic fibrosis).
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EMBARC was approved as an ERS CRC in 2013, 
chaired by J.D. Chalmers from the University of Dundee 
(Dundee, UK) and E. Polverino from the University of 
Barcelona (Barcelona, Spain), with the collaboration 
offices based at the University of Dundee.
Setting up an international 
registry
The primary objective of the EMBARC CRC was the 
creation of a pan-European, prospective registry of 
patients with bronchiectasis [18]. No pan-European 
registries for bronchiectasis existed prior to 2015, 
with only a small number of countries or individual 
regions within countries having registries [22].
In developing the registry, the project 
coordinators followed EU guidance on the 
development of rare disease registries [23, 24]. 
The recommendations from the EU Committee 
of Experts on Rare Diseases (EUCERD) are shown 
in table 1, along with the mechanisms used by 
EMBARC to address these recommendations [23].
The EMBARC registry used a “hub and spoke” model 
to grow the registry across Europe, initially recruiting 
national experts or “champions” in individual 
countries who acted as the initial recruiting centres, 
and assisted with obtaining ethical/institutional 
review board approval and recruiting other centres 
in their respective countries, with the support of 
FIRS and the ERS national delegates. This was 
supplemented with e-mail invitations to participate 
through ERS Assembly 10 and publicity surrounding 
the launch of the registry at the ERS International 
Congress. This resulted in the recruitment of >150 
centres in >40 countries (including both EU and 
non-EU countries) (figure 2). Importantly, EMBARC 
sought to establish a pan-European registry 
rather than merging existing datasets or national 
registries. By defining a core dataset that everyone 
in Europe shared, EMBARC avoided the problem 
of later having to achieve interoperability between 
different registries using different definitions on 
different platforms. This may not be possible for 
all disease areas, where existing infrastructure in 
some countries may already exist.
The EMBARC registry
The EMBARC registry is managed from a data 
coordinating centre in the UK at the University 
of Dundee and received ethical approval in the 
UK in January 2015 (14/SS/1101). The study 
website is www.bronchiectasis.eu. A detailed 
protocol of the study has been published [18]. In 
brief, the inclusion criteria are a clinical history 
consistent with bronchiectasis (cough, chronic 
sputum production and/or recurrent respiratory 
infections) and computed tomography of the chest 
demonstrating bronchiectasis (bronchial dilatation) 
affecting one or more lobes. The exclusion criteria 
are bronchiectasis due to known cystic fibrosis, age 
<18 years and patients that are unable or unwilling 
to provide informed consent (figure 3). Patients 
are followed up on an annual basis with a detailed 
Figure 2 Sites participating in the EMBARC registry as of 
January 2017.
Screening
A clinical history consistent with
  bronchiectasis (cough, chronic sputum 
  production and/or recurrent respiratory 
  infections)
AND
CT scan of chest demonstrating 
  bronchiectasis (bronchial dilation) 
  aecting ≥1 lobes
Exclusion criteria
Bronchiectasis due to unknown cystic fibrosis
Age <18 years
Patients who are unable or unwilling to   
  provide informed consent
Traction bronchiectasis due to interstitial   
  lung disease without clinical bronchiectasis
Previous lung or heart–lung transplantation
Recruitment
Demographics
Comorbidities
Lung function and 
  morbidity
Quality of life
Annual follow-up
Mortality, cause of death
Repeat data for all fields above
Aetiology   
  testing
Microbiology
Radiology
Treatments
Figure 3 The EMBARC registry flow chart. CT: computed tomography. Reproduced from [18].
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review case report form [18]. To date, the registry 
has recruited >8000 patients in just over 2 years 
of recruitment.
Data access rules and 
governance
Involvement of all relevant stakeholders, and fair 
and open access to data is essential for the success 
of large-scale registries and studies. EMBARC has 
achieved this by involving key opinion leaders and 
experienced bronchiectasis researchers in a registry 
steering committee that has guided the project from 
2014 to 2017 (https://www.bronchiectasis.eu/
steering-commitee), by maintaining an international 
advisory board that includes the leads for the key 
non-European registries and experts representing 
four continents (https://www.bronchiectasis.eu/
international-advisory-board), and by having a 
transparent data access policy.
Patients contribute their time to participating 
in research, and contribute their data to a registry 
because they want to see the data used to improve 
clinical care and to bring forward advances in 
medical research. The EMBARC registry has 
therefore been developed with the principle that 
data should be a freely available as possible, and 
that the results of the study should be disseminated 
as widely as possible in order to have the greatest 
possible impact on health and patient care.
The process of applying for data access is 
simple. The data access application form can be 
downloaded from https://www.bronchiectasis.eu/
dataaccess
Governance processes surrounding data 
management and access are fully compliant 
with the UK Data Protection Act 1998, and Data 
Protection Directive 95/46/EC of the European 
Parliament and of the Council (1995) (this will 
be updated when the new EU data protection 
regulations take effect) [18].
A scientific committee, consisting of up to seven 
academic members of the EMBARC network, review 
all data requests to ensure scientific quality, and 
to plan the most appropriate publication and 
dissemination plans for registry data.
A crucial component of a successful network 
is a transparent, democratic and open approach. 
All positions within EMBARC committees and 
working groups are elected. Decision making is 
transparent with consultation and voting among 
the relevant committees where required. An 
annual meeting of the whole EMBARC network is 
held at the ERS International Congress each year 
with more regular meetings of the executive and 
steering committees. All of the major contributing 
countries to EMBARC have a representative that 
forms part of the governance structure, ensuring 
that each contributing country has an equal voice 
in decision making.
Patient involvement
EMBARC works closely with the European Lung 
Foundation (ELF) (www.europeanlung.org), which 
was established by the ERS in 2000 with the aim 
of bringing together patients and the public with 
respiratory professionals to positively influence lung 
health. The design of the registry and all EMBARC 
activities have been informed by review and 
feedback from patients and patient groups [26, 27]. 
The ELF and EMBARC have ensured ongoing patient 
involvement in the network through the creation 
of a patient advisory group (PAG) consisting of 
people with bronchiectasis and those affected by 
bronchiectasis, such as parents, partners or children 
of someone with bronchiectasis. All EMBARC 
projects and meetings now involve patient 
representatives.
Achievements of EMBARC
The EMBARC registry represents a major 
achievement in the field of bronchiectasis given 
the lack of coordinated research activity prior to the 
commencement of the EMBARC study in 2015. The 
EMBARC protocol was published in 2016 and the first 
data publications from the EMBARC registry will be 
submitted for publication in mid- to late 2017 [18]. 
In addition to the registry, EMBARC has contributed 
to the field in a number of important ways since 
2012 as described below.
Publications
EMBARC aligned 10 datasets from different 
European countries, which were collected by 
investigators prior to the start of the EMBARC 
registry in 2015 [28–34]. This approach of 
pooling existing datasets is commonly utilised 
in other diseases; for example, cystic fibrosis and 
primary ciliary dyskinesia [35, 36]. By standardising 
definitions, end-points and covariate data-
points, a dataset of >2000 patients has been 
built for epidemiological studies. The dataset 
is designated FRIENDS (Facilitating Research 
Into Existing National Datasets) [28–34]. This 
cohort was used to derive and validate the first 
multicomponent clinical prediction tool for 
bronchiectasis, the bronchiectasis severity index 
(BSI) [37]. The study showed that a small number 
of key parameters were associated with mortality, 
hospital admissions, quality of life and future 
exacerbations [37]. Specifically, the BSI consists 
of age, functional status (Medical Research Council 
dyspnoea score), forced expiratory volume in 1 s 
(FEV1), radiological severity (number of lobes 
involved or the presence of cystic dilatation), 
low body mass index (<18.5), frequency of 
exacerbations, history of hospitalisation for severe 
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exacerbations and the presence of chronic infection 
with bacteria or particularly with Pseudomonas 
aeruginosa. The resulting score is available at www.
bronchiectasisseverity.com [37].
Subsequently, the BSI was compared to a second 
scoring system, the FACED score (FEV1, age, chronic 
colonisation, extension and dyspnoea), for its 
ability to predict clinically relevant outcomes [29]. 
Both scores appear to perform equally well for the 
prediction of mortality across several cohorts but 
the EMBARC study of 1612 patients found that the 
BSI also predicted hospital admissions for severe 
exacerbations, moderate exacerbations, quality of 
life, respiratory symptoms, and even 6-min walk 
distance and lung function decline [29]. In contrast, 
the FACED score did not consistently predict any 
relevant clinical outcomes beyond mortality [29].
Collaborators from EMBARC have also published 
data demonstrating the characteristics of 
bronchiectasis in the elderly [30], demonstrating 
that only a minority of bronchiectasis patients are 
represented in current randomised clinical trials, 
such as those of inhaled antibiotics and mucoactive 
therapies [31].
A cluster analysis of different clinical 
characteristics performed by Aliberti et al. [32] 
identified four clusters of patients with different 
“phenotypes” and different outcomes. Bacteriology 
in sputum, defined by the presence of P. aeruginosa 
or other bacteria, were key drivers of clinical 
characteristics, while a third cohort was patients 
with daily sputum without chronic colonisation, and 
the final group were patients with dry bronchiectasis. 
Higher levels of neutrophilic inflammation were 
associated with the two bacterial colonisation 
phenotypes, consistent with prior literature [32].
Research priorities identified by the PSG have 
led directly to important EMBARC publications. The 
PAG overwhelmingly felt that comorbid conditions 
were often their most important determinants of 
quality of life. Based on their recommendation, 
the FRIENDS database was used to investigate 
the relative importance of comorbidities to 
disease outcomes in bronchiectasis. Standardised 
definitions of comorbidities were applied across 
the datasets to 986 patients with bronchiectasis. 
Patients had a median of four comorbidities per 
patient (with some patients having up to 20). 13 
comorbidities were independently associated with 
mortality in multivariable analysis [28]. Although 
the individual contribution of each comorbidity was 
modest, multiple comorbidities that could be added 
together as part of an aetiology and comorbidity 
index (Bronchiectasis Aetiology and Comorbidity 
Index) predicted mortality and were associated with 
health-related quality of life as measured by the St 
George’s Respiratory Questionnaire. Patients with 
more comorbidities also had more exacerbations. 
The study confirmed the view of the PAG that 
multimorbidity is a major determinant of quality 
of life and outcomes in bronchiectasis [28].
Further work has defined the most common 
underlying causes of bronchiectasis in Europe, with 
20% being classified as post-infective, 15% due 
to chronic obstructive pulmonary disease (COPD), 
10% due to connective tissue diseases and 6% due 
to immunodeficiency [33]. 13% of cases led to a 
change in patients’ management [33]. De Soyza 
et al. [34] recently confirmed that patients with 
rheumatoid arthritis-associated bronchiectasis 
and COPD have worse clinical outcomes. 
EMBARC researchers have also recently identified 
a series of biomarkers associated with worse 
outcomes [38, 39].
A meta-analysis performed by EMBARC 
researchers identified that patients with P. 
aeruginosa infection are at three-fold increased risk 
of death and seven times more likely to be admitted 
to hospital for severe exacerbations [40].
Improving the quality of care for patients 
with bronchiectasis is also a major priority for 
the network. An audit conducted in Italy showed 
only 32% of patients had aetiological testing 
for allergic bronchopulmonary aspergillosis and 
immunodeficiency, with nearly 60% of patients 
having no aetiological testing [41]. Only 27% 
of patients had a sputum culture once per year. 
Compliance with other quality standards of care 
was similarly low. Improving standards of care 
across Europe is important and will be a major 
objective following the publication of the 2017 
ERS guidelines [41].
World Bronchiectasis Conference
EMBARC held the first international conference 
specifically focussed on bronchiectasis in 2016 in 
Hannover, Germany. The meeting was attended by 
nearly 300 delegates and was a great success both 
in terms of the scientific content and also in raising 
the profile of bronchiectasis. The second EMBARC 
World Bronchiectasis Conference was held in Milan, 
Italy in July 2017 and the third is scheduled for 
Washington, DC, USA, in 2018.
Consensus statements
Expert networks like EMBARC can provide 
important guidance to the field by producing 
consensus statements. The first such document 
was published by EMBARC in 2016 describing 
the research priorities for the field: the European 
Bronchiectasis Research Roadmap [19]. A Delphi 
process was conducted identifying the research 
priorities of a Europe-wide group of experts in 
bronchiectasis. This was complemented by a survey 
of nearly 1000 patients and carers to produce a 
physician/patient consensus of research priorities. 
22 research questions and 55 different studies were 
proposed, emphasising the volume of work there 
is to be done [19] (table 2).
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Exacerbations are the key clinical end-point 
in randomised controlled trials of bronchiectasis 
but all studies to date have used slightly different 
definitions of exacerbation [42–46]. This can have 
a major effect on the results of trials: too stringent 
a definition can result in missing a signal for benefit 
while too loose a definition can result in normal 
day-to-day variation in symptoms or side-effects 
from medications being classified as exacerbations. 
This can dilute a signal for benefit.
To address this, members of EMBARC 
led a consensus working group at the World 
Bronchiectasis Conference in Hannover, in 
collaboration with colleagues from the USA, 
Australia, South Africa and New Zealand [47]. A 
Delphi process identified the key symptoms and 
signs of exacerbation as determined by expert 
opinion, and a resulting simple and operational 
definition of exacerbation was approved and 
published (figure 4). It should be noted this 
definition is for use in clinical trials and is not 
intended to impact clinical care [47].
Such consensus statements, while based on 
expert opinion, can have an important impact on 
the field. Further consensus documents are planned 
in 2017 and beyond.
International bronchiectasis 
networks
In addition to supporting European research, 
EMBARC has made the dataset and platform 
available for international collaborators to use. 
Alignment with other international initiatives is 
a key EUCERD recommendation for registries, 
and allows integrated analysis and higher impact 
outputs. Two excellent examples of partnered 
international networks are the Australian and Indian 
registries.
The Australian registry is an initiative of the 
Lung Foundation of Australia. It collects the “core” 
dataset using the EMBARC platform allowing 
collaborative analyses but also incorporates unique 
Symptoms of a bronchiectasis exacerbation
At least three of:
  Increased cough
  Increased sputum volume or change in sputum 
    consitency
  Increased sputum purulence
  Increased breathlessness and/or decrease exercise 
    tolerance
  Fatigue and/or malaise
  Haemoptysis
Duration of symptoms
Symptoms should be
present for ≥48 h
Physician decision to treat
Physician determines that 
change in bronchiectasis 
treatment is required#
Figure 4 Consensus definition of bronchiectasis exacerbations for use in clinical trials. #: physicians should exclude other 
possible causes of deterioration in symptoms. Reproduced and modified from [47].
Table 2 Selected translational research priorities from the EMBARC roadmap [19]
Key translational research 
questions
Recommendations
What causes bronchiectasis? DNA biobanks linked to well-phenotyped patient cohorts should be established to enable 
underlying genetic susceptibility to bronchiectasis to be established.
What causes bronchiectasis 
exacerbations?
A comprehensive study enrolling patients when stable and during exacerbation should be 
conducted, evaluating the impact of bacteria, viruses, fungi and noninfectious stimuli to 
identify the cause(s) of bronchiectasis exacerbations.
Development of new 
therapies and biomarkers
A deeper understanding of the inflammatory pathways in bronchiectasis is needed to develop 
new therapies. We recommend using emerging techniques and technologies (particularly 
proteomics, metabolomics and genomics) in large, well-characterised cohorts to identify 
new treatment targets and deeper patient phenotyping.
How does the microbiome 
impact patient outcomes in 
bronchiectasis?
We suggest studies of the microbiome (incorporating bacteria and potentially fungi) in 
bronchiectasis linked to detailed clinical phenotyping data.
Why do some patients become 
infected with Pseudomonas 
aeruginosa?
Mechanistic studies investigating the genetic, microbiological, inflammatory and clinical 
susceptibility factors for P. aeruginosa colonisation should be conducted.
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Australian features, such as a paediatric component 
and data fields related to indigenous Australians, 
among others [48, 49]. This demonstrates the 
value of having a core dataset while permitting 
the flexibility to explore local strengths and key 
research questions at a local level. The Indian 
registry (EMBARC-India) is further example of this. 
Coordinated by the Respiratory Research Network 
of India and collecting data across 25 sites, this 
dataset represents the first attempt to understand 
the impact of bronchiectasis in south-east Asia 
where virtually no data have been published. 
The first results were presented at the American 
Thoracic Society Conference in 2017, with 680 
patients reported. In contrast to European cohorts, 
the majority of patients were male (60%) and post-
tuberculosis was the most frequent underlying 
cause (35.7%) [50].
More and more countries are developing 
bronchiectasis research infrastructure using 
the EMBARC platform as a basis for ensuring 
interoperability and future intercontinental 
research.
Randomised controlled trials
EMBARC ultimately wishes to facilitate and support 
randomised controlled trials within its network. At 
the time of writing, EMBARC is actively supporting 
three randomised controlled trials of new therapies 
for bronchiectasis. The registry provides a powerful 
tool for planning and executing trials, by allowing 
feasibility studies to determine how changes in 
protocol design may impact recruitment, and by 
identifying which sites are most likely to contribute 
to trials and can be used to actively encourage 
investigators to take part in trials. The registry and 
EMBARC network can also provide patient input 
into trial design as well as facilitating expert review.
EMBARC is part of the iABC (Inhaled Antibiotics 
in Bronchiectasis and Cystic Fibrosis) consortium, 
an EU Innovative Medicines Initiative consortium 
that includes a programme to develop tobramycin 
dry powder for inhalation [51]. A phase 2 study is 
currently enrolling in Europe for bronchiectasis 
patients with P. aeruginosa infection.
The future: EMBARC 2
The registry and the associated projects described 
above represent important achievements for a 
previously neglected disease [52–55]. Nevertheless, 
the European Bronchiectasis Roadmap identified 
a series of priorities for research, only around half 
of which can be answered by epidemiological 
studies such as registries. In renewing the EMBARC 
project from 2017 to 2020, EMBARC has developed 
ambitious plans to expand its activities.
There has been little translational research into 
bronchiectasis and its pathophysiology remains 
largely unexplored. From 2017 to 2020, EMBARC 
will expand an international bioresource, using 
the registry as a backbone to build a repository 
of blood, DNA, sputum and other biological 
materials for use in translational research. This 
study will allow detailed studies on airway and 
Educational questions
1. Which of the following statements regarding the EUCERD 
recommendations for rare disease registries is correct?
a. To ensure data quality, data entry to registries should always be 
performed by trained healthcare professionals and not directly by 
patients
b. Data quality in routine or electronic healthcare records is typically 
poor, and should not be integrated with registry data
c. Registries should be made available to perform feasibility studies 
for randomised controlled trials
d. European centres of excellence for rare or complex diseases do not 
have a responsibility to contribute to registries
e. Pooled analysis of data with registries outside of Europe is not 
permitted by data protection regulations
2. Which of the following statements regarding registry governance are 
correct?
a. There are no specific European/EU data protection requirements 
and so processes should be determined by requirements at 
national level on a case-by-case basis.
b. It is easier and more efficient to establish individual registries at 
national levels and then develop algorithms to integrate datasets 
than it is to have a single pan-European database
c. Centres participating in registries generally do not require funding 
for this activity
d. EUCERD guidelines suggest that industry should never be involved 
in registry governance
e. Data access procedures should be simple, and ensure that all 
relevant stakeholders can access data where it is in the public 
interest
3. Which of the following features have not been identified as 
determinants of bronchiectasis severity in EMBARC studies?
a. Post-infective aetiology
b. A history of rheumatoid arthritis
c. A history of three or more exacerbations per year
d. Chronic infection with P. aeruginosa
e. Low FEV1
4. Which of the following statements regarding bronchiectasis registries 
internationally is not correct
a. Pulmonary tuberculosis is an important underlying cause of 
bronchiectasis in India
b. Pulmonary NTM were isolated in >30% of patients in the USA 
bronchiectasis registry
c. The Australian registry incorporates data on indigenous Australians 
as this group has a high prevalence of bronchiectasis
d. COPD is a rarely reported comorbidity (<5%) in European patients 
with bronchiectasis
e. The finding that comorbidities predict mortality in the EMBARC 
dataset is likely to be a unique finding to Europe
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systemic inflammation, microbiota and genomics 
to answer fundamental questions regarding 
pathophysiology [56–61].
The overlap between COPD, asthma and 
bronchiectasis is a key priority in the field, and 
will be explored in new clinical and translational 
studies within the network [6]. Furthermore, there 
are very few data published on the presentation and 
outcomes of patients with bronchiectasis during 
exacerbation. EMBARC has initiated an exacerbation 
study where patients are enrolled at the onset of 
exacerbation with detailed data collection and 
longitudinal follow-up in the registry. This will 
allow a deeper understanding of presentation and 
outcomes of bronchiectasis exacerbations.
Nontuberculous mycobacterial (NTM) disease 
represents a major healthcare problem linked to 
bronchiectasis [62]. >50% of patients in the US 
bronchiectasis registry have co-existing NTM 
disease, whereas the rate is much lower in 
Europe [25]. Since NTM patients require different 
management to those with bronchiectasis 
without NTM, EMBARC will launch a specific 
registry for NTM, with new data fields and a 
separate governance structure, in 2017 to 
capture and study in greater detail this important 
patient group.
The development of EMBARC from 2017 to 2020 
illustrates what is possible with the support of a 
successful registry and with the support of a group 
of highly motivated international experts.
Conclusion
EMBARC is a successful ERS CRC. The major 
factors in its success are a clear set of objectives, 
engagement from the overwhelming majority 
of experts and stakeholders in the field, a highly 
professional organisational infrastructure, and 
dedicated cooperative members who have a 
unifying goal of improving patient care.
EMBARC has already made an important 
contribution to bronchiectasis research and 
guidelines. Developments in the next 3 years should 
result in an even greater impact, with contributions 
to epidemiology, translational research, advocacy, 
education and clinical trials.
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